Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel

Summary

We previously showed that variability of response to clopidogrel is linked to occupancy of the P2Y₁₂ receptor by clopidogrel active-metabolite, and that maximal platelet aggregation intensity (MAI) measured by light transmission aggregometry (LTA) correlates with occupancy. The present study compared a range of ex vivo platelet tests at various levels of P2Y₁₂ occupancy. After screening with clopidogrel 75 mg/day for seven days, subjects were selected to obtain ‘low’, ‘average’ and ‘high’ responders and randomised to clopidogrel (75 mg/day days 1–10; 300 mg day 11), or placebo. Assays were LTA in platelet-rich plasma using 2, 5 and 20 μM ADP, VerifyNow^® P2Y₁₂, flow cytometric analysis of platelet activation markers and vasodilator-stimulated phospho-protein (VASP) index, and a thromboelastographic test that is sensitive to clopidogrel. The reference test was P2Y₁₂ receptor occupancy, measured by binding of ³³P-2MeS-ADP to platelets. MAI showed the best correlation with P2Y₁₂ occupancy. Similar results were seen with different ADP concentrations and when LTA data were expressed as inhibition of platelet aggregation. A plot of free receptors/cell versus VASP index was biphasic, with poor correlation for low-level P2Y₁₂ occupancy. Sensitivity of the VerifyNow P2Y₁₂ assay decreased at higher clopidogrel responses. Thromboelastography and P-selectin expression had poor correlation with receptor occupancy. In conclusion, LTA data correlate best with P2Y₁₂ occupancy, the gold standard for detecting clopidogrel’s effect at the receptor level. Our results highlight a limitation of the VASP index, which appears unable to distinguish low, average and high responders early after clopidogrel initiation when P2Y₁₂ occupancy is still low.

Keywords

Clopidogrel - flow cytometry - platelet

• References

• 1 Bassand J-P. et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. The Task Force for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes for the European Society of Cardiology. Eur Heart J 2007; 28: 1598-1660.
• 2 Van de Werf F. et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909-2945.
• 3 Anderson JL. et al. ACC/AHA guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction). Circulation 2007; 116: 803-877.
• 4 Antman EM. et al. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the 2002 ACC/AHA 2004 guidelines for the Management of Patients with ST-Elevation Myocardial Infarction). Circulation 2008; 117: 296-329.
• 5 King SB III. et al. 2007 focused update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: (2007 Working Group to Review New Evidence and Update the 2005 ACC/AHA/SCAI Guideline Update for Percutaneous Coronary Intervention). J Am Coll Cardiol 2008; 51: 172-209.
• 6 Hirsch AT. et al. ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). Circulation 2006; 113: e463-e654.
• 7 Sacco RL. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke, cosponsored by the Council on Cardiovascular Radiology and Intervention. Stroke 2006; 37: 577-617.
• 8 Gurbel PA. et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
• 9 Gurbel P, Tantry U. Drug insight: clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006; 3: 387-395.
• 10 Siller-Matula J. et al. Thienopyridines in cardiovascular disease: focus on clopidogrel resistance. Thromb Haemost 2007; 97: 385-393.
• 11 Neubauer H. et al. How to optimise clopidogrel therapy? Reducing the low-response incidence by aggregometry-guided therapy modification. Thromb Haemost 2008; 99: 357-362.
• 12 De Miguel A. et al. Clinical implications of clopidogrel resistance. Thromb Haemost 2008; 100: 196-203.
• 13 Serebruany V. et al. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008; 100: 76-82.
• 14 Béres BJ. et al. Analysis of platelet α2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost 2008; 100: 829-838.
• 15 Gremmel T. et al. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
• 16 Sibbing D. et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009; 101: 714-719.
• 17 Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: Current status and future directions. Thromb Haemost 2009; 102: 7-14.
• 18 Elsenberg EHAM. et al. The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost 2009; 102: 719-727.
• 19 Zürn CS. et al. ADP-receptor blockade: A case for personalised pharmacotherapy?. Thromb Haemost 2010; 103: 496-506.
• 20 Williams CD. et al. Application of platelet function testing to the bedside. Thromb Haemost 2010; 103: 29-33.
• 21 Sibbing D. et al. Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting. Thromb Haemost 2010; 103: 151-159.
• 22 Montalescot G. et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost 2010; 103: 213-223.
• 23 Sofi F. et al. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
• 24 Malinin A. et al. Validation of a VerifyNow-P2Y₁₂ cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 2006; 28: 315-322.
• 25 Craft RM. et al. A novel modification of the Thromboelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J Lab Clin Med 2004; 143: 301-309.
• 26 Schwarz UR. et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152.
• 27 Gurbel PA. et al. Platelet reactivity in patients and recurrent events post-stenting. Results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005; 46: 1820-1826.
• 28 Hochholzer W. et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006; 48: 1742-1750.
• 29 Pampuch A. et al. Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y₁₂ receptor. Thromb Haemost 2006; 96: 767-773.
• 30 Jakubowski JA. et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2007; 99: 215-222.
• 31 Paniccia R. et al. Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
• 32 Van Werkum JW. et al. A comparison between the Plateletworks™ assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int J Cardiol 2010; 140: 123-126.
• 33 Bal dit Sollier C. et al. Functional variability of platelet response to clopidogrel correlates with P2Y₁₂ receptor occupancy. Thromb Haemost 2009; 101: 116-122.
• 34 Born GV, Cross MJ. The aggregation of blood platelets. J Physiol 1963; 168: 178-195.
• 35 Savi P. et al. P2Y₁₂, a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun 2001; 283: 379-383.
• 36 Savi P, Herbert JM. Use of radiolabeled 2-methylthio-ADP to study P2Y receptors on platelets and cell lines. Methods Mol Biol 2004; 273: 115-124.
• 37 Aleil B. et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92.
• 38 Schäfer A. et al. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y₁₂-specific assay. Thromb Haemost 2008; 100: 618-625.
• 39 Blindt R. et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334.
• 40 Butt E. et al. cAMP- and cGMP-dependent protein kinase phosphorylation sites of the focal adhesion vasodilator-stimulated phosphorylation (VASP) in vitro and in intact human platelets. J Biol Chem 1994; 269: 14509-14517.
• 41 Geiger J. et al. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signalling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999; 19: 2007-2011.
• 42 Jakubowski JA. et al. The use of the VerifyNow P2Y₁₂ point-of-care device to monitor platelet function across a range of P2Y₁₂ inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost 2008; 99: 409-415.
• 43 Varenhorst C. et al. Assessment of P2Y₁₂ inhibition with the point-of-care device VerifyNow P2Y₁₂ in patients treated with prasugrel or clopidogrel coadministered with aspirin. Am Heart J 2009; 157: 562.e1-562.e9.